Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2021 Filed Nov 30, 2021 14:49 UTC |
SHULMAN JOHN DDirector · 10% owner
JCP III SM AIV, L.P.10% owner
METP Holdings LLC10% owner
Juggernaut Partners III GP, L.P.10% owner
Juggernaut Partners III GP, Ltd.10% owner
|
PurchaseWarrant · Derivative | 375,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001104659-21-144901 · tm2134252-1_4.xml · derivative · entry 2 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2026-12-02 F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 14:49 UTC |
SHULMAN JOHN DDirector · 10% owner
JCP III SM AIV, L.P.10% owner
METP Holdings LLC10% owner
Juggernaut Partners III GP, L.P.10% owner
Juggernaut Partners III GP, Ltd.10% owner
|
PurchaseCommon Stock, par value $0.0001 per share | 500,000 | $3.00 | $1,500,000.00 |
DisclosureSEC source: 0001104659-21-144901 · tm2134252-1_4.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,557,771 F1 · balance_after: See Note (1) in Exhibit 99.1. F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| October 18, 2021 Filed Oct 21, 2021 08:47 UTC |
SHULMAN JOHN DDirector · 10% owner
JCP III SM AIV, L.P.10% owner
METP Holdings LLC10% owner
Juggernaut Partners III GP, L.P.10% owner
Juggernaut Partners III GP, Ltd.10% owner
|
PurchaseWarrant · Derivative | 1,661,807 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-21-018515 · doc1.xml · derivative · entry 2 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,661,807 Underlying: Common Stock · 1,661,807 shares Expires 2026-10-18 F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| October 18, 2021 Filed Oct 21, 2021 08:47 UTC |
SHULMAN JOHN DDirector · 10% owner
JCP III SM AIV, L.P.10% owner
METP Holdings LLC10% owner
Juggernaut Partners III GP, L.P.10% owner
Juggernaut Partners III GP, Ltd.10% owner
|
PurchaseCommon Stock, par value $0.0001 per share | 1,661,807 | $1.72 | $2,849,999.01 |
DisclosureSEC source: 0001567619-21-018515 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,057,771 F1 · balance_after: See Note (1) in Exhibit 99.1. F2 · balance_after: Includes 185,414 shares of Common Stock previously held of record by Metuchen Therapeutics, LLC ("MT") that were received by JCP III SM AIV, L.P. as a liquidating distribution. In prior reports, the reporting persons beneficially owned the 185,414 previously held by MT. F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| May 11, 2021 Filed Aug 5, 2021 22:02 UTC |
Arnold MitchellPrin. Acct. Off/Prin. Fin. Off
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001567619-21-014526 · doc1.xml · derivative · entry 1 Arnold Mitchell · CIK 0001841497 · Prin. Acct. Off/Prin. Fin. Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the first annual anniversary of the date of grant and 40% shall vest upon the second annual anniversary of the date of grant. Read SEC document |
| May 11, 2021 Filed Aug 5, 2021 22:01 UTC |
Gesek AndrewPresident, Timm Medical
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001567619-21-014525 · doc1.xml · derivative · entry 1 Gesek Andrew · CIK 0001833990 · President, Timm Medical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the first annual anniversary of the date of grant and 40% shall vest upon the second annual anniversary of the date of grant. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:17 UTC |
WALKER WAYNE REMELLDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007865 · doc1.xml · derivative · entry 1 WALKER WAYNE REMELL · CIK 0001428761 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:16 UTC |
Bradley GregDirector
|
GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007864 · doc1.xml · derivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:16 UTC |
SHULMAN JOHN DDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007863 · doc1.xml · derivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:15 UTC |
Bernstein BruceDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007862 · doc1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:15 UTC |
Silverman JoshuaDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007861 · doc1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| February 19, 2021 Filed Mar 2, 2021 00:16 UTC |
Boctor FadyPres. & Chief Comm. Officer
|
GrantStock Options (right to buy) · Derivative | 215,669 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001567619-21-005214 · doc1.xml · derivative · entry 1 Boctor Fady · CIK 0001833394 · Pres. & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,669 Underlying: Common Stock · 215,669 shares Expires 2031-02-19 F1 · derivative.exercise_date: The options vested 50% as of February 19, 2021, the date of grant, and the remainder vest in equal installments on the first and second annual anniversaries thereof. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $4.86 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 10 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-11-24 F19 · price: Received in connection with the Transactions in exchange for a stock option to acquire 100,000 shares of Neurotrope common stock for $0.972 per share. F18 · derivative.exercise_date: All shares subject to the option vested in connection with the Transactions. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 9 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2030-03-20 F17 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $0.82 per share. F16 · derivative.exercise_date: All shares subject to the option shall vest on March 20, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $20.30 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 8 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2029-03-15 F15 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $4.06 per share. F14 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $19.65 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 7 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-22 F13 · price: Received in connection with the Transactions in exchange for a stock option to acquire 150,000 shares of Neurotrope common stock for $3.93 per share. F12 · derivative.exercise_date: 28,125 shares subject to the option are vested as of the date hereof and the remaining shares subject to the option shall vest quarterly through January 22, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $44.56 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 6 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2028-03-13 F11 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $8.912 per share. F10 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 33,400 | Not disclosed Strike: $98.10 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 5 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,400 Underlying: Common Stock · 33,400 shares Expires 2027-04-11 F9 · price: Received in connection with the Transactions in exchange for a stock option to acquire 167,000 shares of Neurotrope common stock for $19.62 per share. F8 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $95.50 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 4 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-03-17 F7 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $19.10 per share. F6 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 24,855 | Not disclosed Strike: $52.80 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,855 Underlying: Common Stock · 24,855 shares Expires 2026-11-22 F5 · price: Received in connection with the Transactions in exchange for a stock option to acquire 124,275 shares of Neurotrope common stock for $10.56 per share. F4 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 1,875 | Not disclosed Strike: $96.00 | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2026-08-04 F3 · price: Received in connection with the Transactions in exchange for a stock option to acquire 9,375 shares of Neurotrope common stock for $19.20 per share. F2 · derivative.exercise_date: 1,623 shares subject to the option are vested as of the date hereof and the remaining shares subject to the option shall vest daily through August 4, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 02:10 UTC |
Silverman JoshuaDirector
|
GrantCommon Stock, par value $0.0001 per share | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-131729 · tm2037431-3_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: Received in exchange for 100,000 shares of Neurotrope, Inc. ("Neurotrope") common stock in connection with the transactions (the "Transactions") contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the "the Original Merger Agreement"), as amended by the First Amendment to the Original Merger Agreement (the "First Amendment") , dated as of July 23, 2020 and the Second Amendment to the Original Merger Agreement, dated as of September 30, 2020 (the "Second Amendment" and, together with the Original Merger Agreement and the First Amendment, the "Merger Agreement") by and among Petros Pharmaceuticals, Inc. (the "Company"), Neurotrope, PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company ("Merger Sub 1"), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company ("Merger Sub 2"), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:59 UTC |
Gesek AndrewPresident, Timm Medical
|
GrantCommon Stock, par value $0.0001 per share | 97 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020632 · doc1.xml · nonDerivative · entry 1 Gesek Andrew · CIK 0001833990 · President, Timm Medical 10b5-1 filing: Not disclosed Ownership: Indirect · By Metuchen Therapeutics, LLC Disclosed balance after: 97 F1 · price: Received in exchange for 196.43 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Gesek's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:58 UTC |
Lavan KeithChief Financial Officer
|
GrantCommon Stock, par value $0.0001 per share | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020631 · doc1.xml · nonDerivative · entry 1 Lavan Keith · CIK 0001833345 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Metuchen Therapeutics, LLC Disclosed balance after: 975 F1 · price: Received in exchange for 1964.29 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Lavan's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:57 UTC |
SHULMAN JOHN DDirector · 10% owner
|
GrantCommon Stock, par value $0.0001 per share | 3,382,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020630 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,382,416 F1 · price: See Note (1) in Exhibit 99.1. F2 · ownership.nature: See Note (2) in Exhibit 99.1. Read SEC document |
| December 01, 2020 Filed Dec 28, 2020 19:46 UTC Amendment |
SHULMAN JOHN DDirector · 10% owner
Juggernaut Partners III GP, L.P.10% owner
Juggernaut Partners III GP, Ltd.10% owner
METP Holdings LLC10% owner
JCP III SM AIV, L.P.10% owner
Metuchen Therapeutics, LLC10% owner
|
GrantCommon Stock, par value $0.0001 per share | 3,395,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-021618 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner Metuchen Therapeutics, LLC · CIK 0001836798 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,395,964 F1 · shares: This amended Form 4 is being filed to add Reporting Persons and to adjust the number of securities acquired to account for the same. F2 · price: See Note (1) in Exhibit 99.1. F3 · ownership.nature: See Note (2) in Exhibit 99.1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.